AlphAIAlphAI — Financial news for AI agents
sci-tech-today.comAUG 252 min read$EVAX

Evaxion A/S Q2 2026 Earnings: Revenue Misses $0, Net Loss Narrows

Evaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.

Original reporting
sci-tech-today.com
Published Aug 25, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evaxion A/S Q2 2026 Earnings: Revenue Misses $0, Net Loss Narrows — source image
Source · sci-tech-today.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The earnings release provides the first detailed financial snapshot for Q2 2026, showing cash runway into H2 2027 and pipeline milestones.

02

Market read

Micro‑cap biotech earnings with modest price reaction; relevance mainly for investors tracking cash‑runway and pipeline milestones.

03

What to watch

Upcoming regulatory filing for EVX-04 and ESMO presentation could drive future volatility.

Relevance 6/10Novelty 7/10Timing: early trading on earnings release day

Background

Evaxion A/S is a Denmark‑based clinical‑stage TechBio firm using AI‑Immunology platform for cancer vaccines.

Company-level read

Ticker impact

$EVAXBullishMedium confidence
Context

Q2 2026 earnings released with zero revenue, narrowed net loss and 5.4% share price rise in early trading.

Expected impact

Potential short‑term upside of 3‑5% if investors focus on cash runway and pipeline progress.

Evidence & confidence

Micro‑cap biotech with limited scale; price move modest and driven by cash‑runway narrative rather than material revenue.

Market effects

Sector

Highlights ongoing cash‑burn concerns in clinical‑stage biotech sector.

Regional

Limited to US‑listed small‑cap biotech investors.

Global

Low; primarily relevant to niche biotech investors.

Counterpoint

What could challenge this read

Despite loss narrowing, zero revenue and high dilution risk may outweigh short‑term price gain.

Key entities

  • Executive
    Helen Tayton‑Martin

    CEO who highlighted pipeline progress and cash runway.

Read at source← All news

Related articles

NOV 3
$EVAXMedAI 8/10

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

finanznachrichten.de2 min
OCT 23
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de3 min
OCT 23
$EVAXMedAI 8/10

Evaxion reports three-year data for cancer vaccine EVX-01

Evaxion A/S (EVAX) reported three-year phase 2 trial data for its cancer vaccine EVX-01, showing sustained immune response and no tumor progression in advanced melanoma patients. The data will be presented at the ESMO Congress 2026. EVX-01 is personalized and designed using Evaxion's AI-Immunology platform. The company has a cash runway into mid-2027.

investing.com2 min
OCT 23
$EVAXMedAI 9/10

Six melanoma responders received Evaxion's vaccine alone in year three. None had tumor progression.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

stocktitan.net2 min